X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (74) 74
male (46) 46
female (45) 45
adult (35) 35
middle aged (35) 35
hematology (28) 28
oncology (27) 27
aged (26) 26
bortezomib (25) 25
treatment outcome (19) 19
index medicus (18) 18
boronic acids - therapeutic use (16) 16
pyrazines - therapeutic use (16) 16
transplantation (15) 15
bone marrow (13) 13
cancer (13) 13
multiple myeloma - drug therapy (13) 13
mutation (12) 12
multiple myeloma (11) 11
adolescent (10) 10
boronic acids - adverse effects (10) 10
isocitrate dehydrogenase - genetics (10) 10
leukemia (10) 10
pyrazines - adverse effects (10) 10
recurrence (10) 10
acute myeloid-leukemia (9) 9
aged, 80 and over (9) 9
apoptosis (9) 9
medicine, general & internal (9) 9
protease inhibitors - therapeutic use (9) 9
therapy (9) 9
antineoplastic agents - therapeutic use (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
cells (8) 8
chemotherapy (8) 8
boronic acids - administration & dosage (7) 7
immunology (7) 7
nf-kappa-b (7) 7
prognosis (7) 7
pyrazines - administration & dosage (7) 7
transplantation, autologous (7) 7
bone marrow transplantation (6) 6
dexamethasone - administration & dosage (6) 6
dose-response relationship, drug (6) 6
drug therapy (6) 6
hematopoietic stem cell transplantation (6) 6
lymphoma (6) 6
multiple-myeloma (6) 6
prospective studies (6) 6
proteasome inhibitor ps-341 (6) 6
research (6) 6
survival rate (6) 6
trial (6) 6
tumors (6) 6
bone marrow transplantation - adverse effects (5) 5
boronic acids - pharmacology (5) 5
care and treatment (5) 5
differentiation (5) 5
drug resistance, neoplasm (5) 5
drug therapy, combination (5) 5
follow-up studies (5) 5
gliomas (5) 5
glutarates - blood (5) 5
health aspects (5) 5
leukemia, myeloid, acute - genetics (5) 5
leukemia, myeloid, acute - pathology (5) 5
protease inhibitors - pharmacology (5) 5
ps-341 (5) 5
pyrazines - pharmacology (5) 5
risk factors (5) 5
stem-cell transplantation (5) 5
transplantation, homologous (5) 5
2-hydroxyglutarate (4) 4
activation (4) 4
animals (4) 4
antineoplastic agents - administration & dosage (4) 4
antineoplastic agents - adverse effects (4) 4
antineoplastic agents - pharmacology (4) 4
article (4) 4
bone-marrow transplantation (4) 4
cell line, tumor (4) 4
child (4) 4
colony-stimulating factor (4) 4
cytarabine - administration & dosage (4) 4
dexamethasone (4) 4
dexamethasone - therapeutic use (4) 4
disease-free survival (4) 4
expression (4) 4
isocitrate dehydrogenase - metabolism (4) 4
leukemia, myeloid, acute - blood (4) 4
lung neoplasms - drug therapy (4) 4
malignancies (4) 4
multiple myeloma - pathology (4) 4
non-hodgkins-lymphoma (4) 4
phase-2 (4) 4
phase-ii (4) 4
proteasome inhibitor (4) 4
proteasome inhibitors (4) 4
remission induction (4) 4
retrospective studies (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2003, Volume 348, Issue 26, pp. 2609 - 2617
Journal Article
Science, ISSN 0036-8075, 5/2013, Volume 340, Issue 6132, pp. 622 - 626
A number of human cancers harbor somatic point mutations in the genes encoding isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2). These mutations alter... 
Molecules | Enzymes | Dehydrogenases | Blasts | Myeloid leukemia | REPORTS | Stem cells | Bone marrow cells | Cellular differentiation | Hematopoietic stem cells | Mesenchymal stem cells | ISOCITRATE DEHYDROGENASE | ONCOMETABOLITE 2-HYDROXYGLUTARATE | SUFFICIENT | MULTIDISCIPLINARY SCIENCES | HEMATOPOIETIC PROGENITORS | MUTATION | Cell Proliferation | Humans | Protein Multimerization | Crystallography, X-Ray | Erythropoiesis - drug effects | Isocitrate Dehydrogenase - antagonists & inhibitors | Molecular Targeted Therapy | Hematopoiesis - drug effects | Antineoplastic Agents - metabolism | Leukemia, Myeloid, Acute - enzymology | Phenylurea Compounds - chemistry | Enzyme Inhibitors - chemistry | Leukemia, Myeloid, Acute - drug therapy | Antineoplastic Agents - pharmacology | Phenylurea Compounds - metabolism | Mutant Proteins - antagonists & inhibitors | Catalytic Domain | Enzyme Inhibitors - metabolism | Protein Structure, Secondary | Sulfonamides - chemistry | Leukemia, Myeloid, Acute - pathology | Cells, Cultured | Enzyme Inhibitors - pharmacology | Isocitrate Dehydrogenase - genetics | Mutant Proteins - metabolism | Gene Expression Regulation, Leukemic | Antineoplastic Agents - chemistry | Sulfonamides - pharmacology | Point Mutation | Isocitrate Dehydrogenase - chemistry | Small Molecule Libraries | Mutant Proteins - chemistry | Allosteric Site | Sulfonamides - metabolism | Cell Line, Tumor | Isocitrate Dehydrogenase - metabolism | Glutarates - metabolism | Phenylurea Compounds - pharmacology | Leukemia, Erythroblastic, Acute | Leukemia, Myeloid, Acute - genetics | Leukemia | Cancer cells | Physiological aspects | Research | Oxidoreductases | Cell differentiation | Health aspects | Mutation | Cellular biology | Drug therapy | Cells
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 3946 - 3946
Abstract Somatic point mutations in isocitrate dehydrogenase 1/2 have a gain-of-function neomorphic activity that converts alpha-ketoglutarate to the... 
Journal Article
Journal of Neuro-Oncology, ISSN 0167-594X, 3/2012, Volume 107, Issue 1, pp. 197 - 205
Journal Article
Journal Article
Journal Article
Journal Article
The Oncologist, ISSN 1083-7159, 01/2012, Volume 17, Issue 1, pp. 5 - 8
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2013, Volume 19, Issue 11, pp. 2804 - 2809
For a new therapy to qualify for the accelerated approval pathway, it must treat a serious disease for which there is "unmet medical need"-defined as providing... 
LAPATINIB | TRASTUZUMAB | ONCOLOGY | METASTATIC BREAST-CANCER | PROGRESS | Antineoplastic Agents | Drug Approval | United States | Humans | United States Food and Drug Administration
Journal Article